Immunogenicity, the elephant in the room. Comment on "Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases"

被引：2
|
作者：
Pixley, John [1 ,2 ]
机构：
[1] Univ Nevada, Sch Med, Div Rheumatol, Reno, NV 89557 USA
[2] Univ VA Sierra Heath Care Syst, Div Immunol, Reno, NV USA
来源：
CLINICAL RHEUMATOLOGY | 2013年 / 32卷 / 10期
关键词：
ABATACEPT; ARTHRITIS;
D O I：
10.1007/s10067-013-2364-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1413 / 1413
页数：1
相关论文
共 50 条
  • [1] Immunogenicity, the elephant in the room. Comment on “Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases”
    John Pixley
    Clinical Rheumatology, 2013, 32 : 1413 - 1413
  • [2] ANTI-DRUG ANTIBODIES, DRUG LEVELS AND CLINICAL EFFICACY OF THE ANTI-TNF BIOLOGICS IN RHEUMATIC DISEASES
    Mok, C. C.
    van der Kleij, D.
    Wolbink, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 226 - 226
  • [3] Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
    Mok, C. C.
    van der Kleij, D.
    Wolbink, G. J.
    CLINICAL RHEUMATOLOGY, 2013, 32 (10) : 1429 - 1435
  • [4] Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
    C. C. Mok
    D. van der Kleij
    G. J. Wolbink
    Clinical Rheumatology, 2013, 32 : 1429 - 1435
  • [5] PRIOR IMMUNOGENICITY TO ANTI-TNF BIOLOGICS IS NOT ASSOCIATED WITH INCREASED ANTI-DRUG ANTIBODIES TO VEDOLIZUMAB OR USTEKINUMAB
    Costable, Nicholas J.
    Borman, Zachary A.
    Phan, Becky L.
    Ji, Jiayi
    Dubinsky, Marla
    Ungaro, Ryan C.
    GASTROENTEROLOGY, 2020, 158 (06) : S468 - S469
  • [6] Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab
    Costable, Nicholas J.
    Borman, Zachary A.
    Ji, Jiayi
    Dubinsky, Marla C.
    Ungaro, Ryan C.
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (06) : 2480 - 2484
  • [7] Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab
    Nicholas J. Costable
    Zachary A. Borman
    Jiayi Ji
    Marla C. Dubinsky
    Ryan C. Ungaro
    Digestive Diseases and Sciences, 2022, 67 : 2480 - 2484
  • [8] BARRIERS AGAINST TESTING ANTI-TNF DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN ROUTINE CLINICAL PRACTICE
    Gavan, S. P.
    Daker-White, G.
    Payne, K.
    Barton, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1726 - 1727
  • [9] Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease
    Ha, Christina
    Mathur, Jagrati
    Kornbluth, Asher
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (04) : 497 - 505
  • [10] LOW DRUG CONCENTRATIONS AND ANTI-DRUG ANTIBODY FORMATION TO THE PRIOR ANTI-TNF PREDISPOSES PATIENTS WITH INFLAMMATORY BOWEL DISEASE TO DEVELOP ANTI-DRUG ANTIBODIES TO THE SUBSEQUENT ANTI-TNF
    Cheifetz, Adam S.
    Abreu, Maria T.
    Flier, Sarah N.
    Papamichail, Konstantinos
    Rieder, Florian
    Silverberg, Mark S.
    Khanna, Reena
    Okada, Lauren
    Yang, Lei
    Jain, Anjali
    Vande Casteele, Niels
    GASTROENTEROLOGY, 2020, 158 (06) : S457 - S457
12345